Avalyn Pharma Stock

Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.

Sign up today and learn more about Avalyn Pharma Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Avalyn Pharma Stock

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Funding History

January 2017$62.0M
April 2020$35.5M
September 2023$175M

Management

Founder and CSO

Mark W. Surber

Board Member

Jill Carroll

Board Member

Gianna Hoffman-Luca

Chief Financial Officer

Marc Schneebaum

CEO

Lyn Baranowski

Chief Operating Officer

Melissa Rhodes

CEO

Bruce Montgomery

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo